Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and its Genentech subsidiary are planning to hitch up their cardiovascular,

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second IV bolus administration

Roche will be the first to join Harvard's Enterprise Research Campus in Allston, taking a suite in the first phase of the project's cutting-edge lab space Starting with a lease of 30'000 square feet,

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded indication. "TNKase provides a faster and simpler admin

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.

Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which ...

Roche, announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such as disease biology,